WSD1227 / Wayshine Biopharm - LARVOL DELTA

WSD1227: A BBB penetrable VEGFR small molecule for the treatment of primary and metastatic brain tumors (AACR 2019) - "WSD1227 treatment resulted in significant anti-tumor activity in VEGF related extracranial and intracranial mice models, with superior efficacy than bevacizumab. In addition, WSD1227 is predicted to be CNS penetrable with decent PK in human. Taken together, our data provide a good rationale for WSD1227 to be developed toward clinic to investigate anti-angiogenetic therapies for management of patients with primary or metastatic brain tumors."